Detection and quantification of circulating proteins are optimized with Olink Proteomics® Proximity Extension Assay (PEA) technology, and protein biomarker detection services from Azenta Life Sciences. Unlike traditional methods, this approach enables high-throughput, simultaneous analysis of proteins with high specificity and sensitivity using minimal sample amounts. As a Certified Service Provider (CSP) for Olink Proteomics, we offer uniquely scalable solutions from highplex Olink Explore HT, to midplex Target 48 and 96 assays, down to customized Flex and Focus assays. Processing is available for research use only (RUO) or can be performed in our GCP-compliant CAP-accredited, CLIA-certified laboratory for clinical applications.

As part of a multiomics approach, this proteomics service can be combined with Azenta’s genomic and transcriptomic solutions to provide a comprehensive understanding of molecular changes contributing to development, disease, and drug response in clinical trials.



What is Proteomics and Why Does It Matter?

Proteomics, the study of proteins, provides a comprehensive picture of disease phenotypes and mechanisms at the functional site. Through proteomics at a population scale, scientists can identify causal proteins, uncover novel pathways, and discover potential therapeutic targets. This holistic approach has the potential to revolutionize drug development.

The Power of Proteomics

Discover how scientists are using Olink® Proteomics to advance target
discovery and reshape the outcomes of their clinical studies.



Drug Target Identification & pQTLS


Biomarker Analysis & Screening


Patient Stratification


Predicting Drug Response

Learn more about why researchers and clinicians include Olink Proteomics in their studies.


Genomics, transcriptomics, epigenomics, and proteomics individually provide unique and crucial insight into the inner workings of human cells. Collectively, these multiomic tools can provide detailed insights into relationships and patterns to help you accelerate and expand your search for drug targets.


Uniquely Scalable Proteomics

Olink platforms scale from highplex Olink HT/5400 and Olink Explore 3072, to midplex Olink Target 48 and Olink Target 96, down to customized lowplex Olink Focus and Olink Flex.

Explore HT Explore 3072/384 Target 96 Target 48 Flex & Focus
Olink Explore HT is the next generation solution for high-throughput proteomics. Containing over 5400 proteins with proven specificity, Olink Explore HT has 100% coverage of top-level pathways. Comprised of eight 384-plex human disease focused panels, Olink Explore is both flexible and scalable; you may run the entire library or focus on one or more of the 384-plex panels. With Olink Target 96, choose from fifteen carefully designed panels built for specific areas of human disease and key biological processes. For researchers working with mouse models, Target 96 Mouse Exploratory is also available. One of the broadest human cytokine inflammation panels available, Olink Target 48 allows for analysis of proteins with the highest relevance for investigation of inflammatory processes and diseases to support clinical trials. With Olink’s made-to-order products, Olink Flex and Olink Focus, researchers can select and combine targets for up to 21 human proteins in one biomarker panel.
The most comprehensive panel yet, Explore HT includes 2,536 new biomarkers. With Olink Explore HT, just 2 µL of sample are consumed to measure over 5,300 proteins. Data are available via NPX values, or Normalized Protein Expression, for relative protein quantification. Eight available panels organized into four disease areas:
  • Cardiometabolic I & II
  • Neurology I & II
  • Inflammation I & II
  • Oncology I & II
Disease area:
  • Cardiovascular Disease II, Cardiovascular Disease III, Oncology, Oncology III, Neurology, Inflammation, Immuno-oncology
Biological process:
  • Cardiometabolic, Cell regulation, Neuro-exploratory, Immune Response, Development, Metabolism, Organ Damage
Use the Target 48 cytokine panel to elucidate:
  • In vitro therapeutic effects on the number of cytokines produced
  • Candidate biomarkers for predicting response and/or toxicity
  • The immune system mechanism of action by coupling Target 48 cytokine panel with gene expression (RNA) data
  • Immunogenicity induced by your agent in vivo
Choose and combine pre-validated assays from Olink's extensive biomarker library. The assays have 99% combinability and maintains the quality, performance, specificity, and sensitivity associated with standard Olink panels. The data is reported in absolute (pg/mL) or relative (NPX) quantification.
Click to download the assay list:
Explore HT Protein Panels >
Click to download the assay list:
Explore 3072/384 Protein Panels >
Click to download the assay list:
Target 96 Protein Panels >
Click to download the assay list:
Target 48 Protein Panels >
Click to download the assay list:
Flex/Focus Protein Panels >




Standard Deliverables

  • Absolute quantification in pg/ml (Olink Target 48 only)
  • Data in Normalized Protein Expression (NPX) format for relative quantification
  • Certificate of Analysis showing quality details – internal and external controls are included throughout the workflow to ensure data quality

Advanced Analysis

(In addition to standard deliverables)

  • Data visualization: Provides a principal component analysis and heatmap to visualize sample distribution and protein expression – results are illustrated from differential expression analysis in both table and interactive-graphic formats
  • Statistical analysis: Includes differentially expressed protein analysis – input will be absolute quantification value for Olink Target 48 or NPX value for Olink Target 96

Custom bioinformatics analysis and reports are available. Please contact us about how we can customize your analysis to answer your biological question.


Features and Benefits


  • Building

    Olink Certified Service Provider (CSP)

    Global CSP for Olink Explore HT and Olink Target products (48, 96, Flex and Focus)

  • Building

    Sample and Material Management

    Offering storage and transport of your samples

  • Building

    Fast Turnaround

    Starting at just 10 business days for expedited projects

  • Building

    CAP/CLIA Processing

    Processing available in our GCP- compliant CLIA/CAP laboratory for clinical applications

Uniquely scalable solutions with optional panel sizes and expandable multiomic solutions across DNA, RNA, Protein
As little as 1 µL needed for analysis, with 40 µL recommended for sample submission
Dual-recognition of two antibodies and DNA barcoding unique to each protein enables high specificity of protein detection – no readout of cross-reactivity
High sensitivity for protein detection, similar to ELISA or better
Increased precision (average intra %CV <10% and inter %CV <20%) across multiplex and midplex assays
Dynamic range spanning more than 10 logs, which makes it ideal for the study of the plasma proteome

Get Rewarded for Your Referrals

Unlock 20% off your next genomics order*

*Terms & conditions apply

Blog │ The Power of Proteomics

The landscape of drug development is constantly evolving, fueled by groundbreaking scientific advancements. While genetics has played a central role in understanding diseases, proteomics provides a more comprehensive picture of disease phenotypes and mechanisms. In this blog, discover how researchers and clinicians are using Olink proteomics to reshape the outcomes of their clinical studies.

Blog | Comparing Mass Spectrometry, ELISA, and Olink for Proteomics

The field of proteomics has evolved significantly in the last decade, with several technologies now available to assay protein biomarkers in clinical studies. In this article, we compare three popular approaches for proteomics - mass spectrometry, ELISA, and the Olink® Proximity Extension Assay (PEA) - and highlight their strengths and limitations.

White Paper │ Multiplex Analysis of Inflammatory Proteins: A Comparative Study Across Multiple Platforms

Multiplexing technologies are often challenged by cross-reactive binding or interference contributing to the signal readout, which can lead to poor specificity. Olink®'s proprietary PEA technology circumvents these challenges by use of a dual recognition approach with matched pairs of antibodies labeled with complimentary DNA oligos. This white paper verifies the quality of Olink technology relative to two common multiplex proteomics platforms widely used in protein biomarker research.

Tech Note | Proteomic Biomarker Discovery to Support Clinical Trials

Traditionally preclinical exploratory research and clinical trial biomarker detection and measurement have been restricted to a few indicators measured by mass spectrometry and ELISA. Discover how Azenta has implemented fully validated protein biomarker discovery services using the Olink® Proximity Extension Assay (PEA) technology capable of detecting and measuring hundreds to thousands of proteins simultaneously.

Tech Note | High-Plex Exploratory Biomarker Discovery to Support Proteomics and Multiomics Research

The development of novel strategies for mid-to high-plex protein detection and quantification enables greater utilization of protein biomarkers across the drug discovery and development process. Using Olink® Proximity Extension Assay (PEA) technology, Azenta has deployed fully validated protein biomarker discovery services for up to 1 million data points per experiment with comparable sensitivity to traditional methods and utilization of lower sample amounts.

Blog | How Olink technology is revolutionizing proteomics and multiomics

Current proteomics technologies often present limitations in terms of throughput, specificity, and cost. However, new innovations, such as Olink Proteomics’ PEA technology, are overcoming these challenges by enabling hundreds to thousands of proteins to be measured in a single sample. In this blog, discover how Azenta is leveraging PEA technology for protein biomarker discovery, its applications, and how it can complement genomics data to accelerate drug development.

Webinar | Precision Proteomics: How to Enable Biomarker Identification in Health and Disease

Hear directly from Olink Proteomics about precision protein analysis as a tool to improve health outcomes for patients with cancer, inflammatory, or age-related diseases. Take this chance to discover how you can bring your protein biomarker discovery to the next level with Olink PEA technology.

Webinar | Do More with Less: Harnessing the Power of Multiomics from a Single Sample

The -omics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexities underpinning human health. In this recording from the Azenta Life Sciences Breakfast Talk at ASHG 2022, Dr. Andrea O’Hara presents a workflow to rapidly produce a diverse set of multiomics results, including genomics, epigenomics, transcriptomics, and proteomics, from a single blood draw. 

Poster | A Demonstrated Workflow to Unleash the Multiomic Potential of a Single Blood Draw

The multiomics era has greatly expanded the repertoire of approaches available for researchers and clinicians to unravel the complexity underpinning human health. Explore how the single blood draw multiomics workflow from Azenta Life Sciences can drive more significant insights and innovation in human health applications.


For information on our NGS platforms as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing-only projects.

10x Genomics

How To Order

Email | Phone 1-877-436-3949, Ext. 1